


DFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



Initial Application of

**THUROW, H.**

Examiner: CORDERO GARCIA, Marcela M

Application No.:

**10/632,414**

Art Unit: **1654**

Filed:

**August 1, 2003**

Title: **A Method for Purifying Preproinsulin**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

**July 15, 2005**

Date of Deposit

Brian Pritchett  
Signature

*Brian Pritchett*

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

07/19/2005 SFELEKE1 00000025 181982 10632414  
01 FC:1806 180.00 DA

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


Based on the new USPTO procedures, it is not required to submit copies of U.S. patents and U.S. publications for all applications filed after June 30, 2003. Therefore, a copy of the 3 (three) U.S. Patent Documents listed on the attached PTO-1449 form are not enclosed with this Information Disclosure Statement. Please note that the three U.S. patents are English language equivalents as follows:

U.S. 5,473,049 – is english equivalent to EP 0600372

U.S. 5,358,857 – is english equivalent to EP 0489780

U.S. 4,783,441 - is english equivalent to EP 0018609

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626  
Aventis Docket No. DEAV2002/0053 US NP



Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/632,414	
			Filing Date	08-01-2003	
			First Named Inventor	THUROW	
			Group Art Unit	1654	
			Examiner Name	CORDERO GARCIA, Marcela M.	
Sheet	2	of	2	Attorney Docket Number	DEAV2002/0053 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BRANGE, J. et. al., Toward Understanding Insulin Fibrillation, Journal of Pharmaceutical Sciences, Vol.86, No. 5 May 1997	
		DE BERNARDEZ, E. et. al., Inhibition of Aggregation Side Reactions during in Vitro Protein Folding , Methods in Enzymology, Vol. 39, pp. 217-236 (1999)	
		KEMMLER, W., et. al. , Studies on the Conversion of Proinsulin to Insulin, The Journal of Biological Chemistry Vol.246, No. 22 pp.6786-6791	
		RATNER, R., et. al., Persistent Cutaneous Insulin Allergy Resulting from High-Molecular-Weight Insulin Aggregates , Diabetes, Vol. 39, (1990) pp.728-733	
		STEINER, D.F., Isolation and Properties of PProinsulin, Intermediate Forms, and Other Minor Components from Crystalline Bovine Insulin, Diabetes, Vol.17, No.12 pp. 725-736 (1968)	
		THUROW,H., Stabilisation of Dissolved proteins against Denaturation at Hydrophobic Interfaces, Diabetologia (1984), Vol.27, pp.212-218	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor Application of  
**THUROW, H.**

Examiner: CORDERO GARCIA, Marcela M.

Art Unit: 1654

Application No.: **10/632,414**

Filed: **August 1, 2003**

Title: **A Method for Purifying Preproinsulin**

**Certificate of Mailing or Transmission**  
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.  
Date of Deposit July 15, 2005  
Printed Name of Person Signing Certificate Brian Pritchett  
Signature Brian Pritchett


**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,

  
Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0053 US NP